We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 535.00 | 521.00 | 524.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMSLN
RNS Number : 5183L
Silence Therapeutics PLC
19 April 2018
Additional listing
19 April 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has issued and allotted 48,309 new ordinary shares of 5p each ("Ordinary Shares") following the exercise of share options under the Employee Share Scheme.
Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 25 April 2018. The Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.
The total number of shares in issue, following admission, will be 70,069,933. The Company holds no shares in Treasury.
Enquiries:
Hot Features
Premium
Silence Therapeutics plc Tel: +44 (0)20 3457 6900
Ali Mortazavi, Chief Executive Officer
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Tel: +44 (0)20 7418 8900
Broker)
James Steel/Oliver Jackson
Media Enquiries:
Optimum Strategic Communications Tel: +44 (0) 20 3714 1788
Mary Clark/ Eva Haas/Hollie Vile
silence@optimumcomms.com
IR Enquires - US Tel: +1 (212) 213 0006
Burns McClellan
John Grimaldi
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSGGUMWCUPRGCB
(END) Dow Jones Newswires
April 19, 2018 12:00 ET (16:00 GMT)
1 Year Silence Therapeutics Chart |
1 Month Silence Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
